ENTEGRION is an innovative
life sciences development company specializing in technologies that
fill clearly defined, unmet market needs.
Entegrion announces the addition of Brian Gibler to its board of directors
Research Triangle Park, NC, July 31, 2012 –The life sciences development company Entegrion announced today it has been awarded $1.9 Million from the U.S. Office…moreMore NEWS
Our proprietary dehydrated pathogen-inactivated human plasma breaks cold chain storage and offers plasma therapy to remote and austere conditions.
Our Goal: Demonstrate enhanced safety and equivalent efficacy for transfusion recipients through the reduction of non-enveloped viruses and elimination of pro-inflammatory factors that can lead to morbidity and mortality.